Foundation Fighting Blindness

The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.

Episodes

Nanoscope’s investigational RP treatment MOGENRY advances toward FDA approval

September 18, 2026 • 5 mins

The U.S. Food and Drug Administration accepted Dallas-based Nanoscope Therapeutics' biologics license application for MOGENRY, an emerging treatment for adults with retinitis pigmentosa and severe vision loss. The investigational treatment does not require a genetic diagnosis or specific gene mutation, giving MOGENRY the potential to become the first approved gene-agnostic treatment to improve vision in people with severe vision lo...

Listen

Watch

Mark as Played

Eye on the Cure Podcast | Episode 103: Kenyetta McCurdy-Byrd and Heather Edwards

September 2, 2026 • 50 mins

Two non-profit professionals talk about plugging into community and finding low-vision resources through the Foundation

Listen

Watch

Mark as Played

First patient treated with potential retinitis pigmentosa treatment from Sumitomo Pharma America

August 27, 2026 • 2 mins

Sumitomo Pharma America treated its first patient in a Phase 1/2a clinical trial for an emerging retinitis pigmentosa (RP) treatment called DSP-3077. The clinical trial plans to treat 12 adults with one of two different doses to evaluate safety and effectiveness of the treatment among patients who have RP.

Listen

Watch

Mark as Played

Tarsus plans to purchase Alkeus, developer of emerging Stargardt treatment

August 24, 2026 • 3 mins

Tarsus Pharmaceuticals announced plans to acquire Alkeus Pharmaceuticals, including its emerging oral treatment for Stargardt disease, gildeuretinol (ALK-001), in a deal valued up to $800 million. Stargardt disease is the most common form of inherited macular degeneration and is often diagnosed in children or teens. There are no current treatments.

Listen

Watch

Mark as Played

PRIMA retinal implant restores sight in patients with geographic atrophy from AMD

August 19, 2026 • 3 mins

In Europe, Science Corporation has commercially launched PRIMA, a retinal implant designed to restore central vision in people with geographic atrophy (GA). The treatment has been shown in clinical trials to restore functional central vision in people with GA who until now had no way to get lost central vision back. While PRIMA is available in Europe, it is still going through FDA approvals in the U.S. Geographic atrophy is an adva...

Listen

Watch

Mark as Played

FDA accepts new drug application, prioritizes review for potential Stargardt treatment

August 14, 2026 • 4 mins

Belite Bio’s tinlarebant could become the first-ever approved treatment for Stargardt disease

Listen

Watch

Mark as Played

Eye on the Cure Podcast | Episode 102: What is Venture Philanthropy?

August 5, 2026 • 30 mins

Dr. Alicia Kemble explains how the Foundation is using venture philanthropy to drive treatments for inherited retinal diseases even closer to the finish line.

Listen

Watch

Mark as Played

Sepul Bio completes clinical trial enrollment for its USH2A retinitis pigmentosa treatment

July 24, 2026 • 3 mins

Sepul Bio recently announced that it completed enrollment of its Phase 2b safety and efficacy clinical trial for ultevursen – an investigational RNA therapy to treat patients who have retinitis pigmentosa (RP) associated with mutations in the USH2A gene.

Listen

Watch

Mark as Played

FDA approves Lumvoa, a new treatment for thyroid eye disease

July 15, 2026 • 5 mins

FDA approves Lumvoa, a new treatment for thyroid eye disease by Foundation Fighting Blindness

Listen

Watch

Mark as Played

Belite Bio submits new drug application to FDA for its Stargardt treatment

July 6, 2026 • 3 mins

Belite Bio submits new drug application to FDA for its Stargardt treatment by Foundation Fighting Blindness

Listen

Watch

Mark as Played

Eye on the Cure Podcast | Episode 101: Dr. Patrick Staropoli

July 1, 2026 • 42 mins

New host Maddie Mossman interviews retinal surgeon Dr. Staropoli, the first medical doctor to win a NASCAR race.

Listen

Watch

Mark as Played

Potential Oral Stargardt Treatment Advances to Phase 3 Clinical Trial

June 18, 2026 • 4 mins

Promising oral treatment moves closer for Stargardt patients.

Listen

Watch

Mark as Played

Foundation Fighting Blindness Celebrates Bennett, Maguire, and High's Breakthrough Prize for Revolutionary Gene Therapy

May 11, 2026 • 4 mins

2020 Llura Liggett Gund Award recipient honored for pioneering gene therapy that transformed vision research

Listen

Watch

Mark as Played

Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis

April 21, 2026 • 3 mins

Data monitoring committee recommends proceeding with registration-enabling study for ATSN-201

Listen

Watch

Mark as Played

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

April 16, 2026 • 3 mins

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) by Foundation Fighting Blindness

Listen

Watch

Mark as Played

Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline

April 8, 2026 • 2 mins

Strategic funding extends cash runway through 2029 and advances multiple inherited retinal disease programs

Listen

Watch

Mark as Played

VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy

March 26, 2026 • 2 mins

VG801 shows sustained vision improvements through 12 months with favorable safety profile

Listen

Watch

Mark as Played

Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment

March 24, 2026 • 2 mins

Potential cell therapy, DSP-3077, gains special regulatory status to support development for inherited retinal disease.

Listen

Watch

Mark as Played

Octant Bio Begins Clinical Testing Oral Treatment for Rhodopsin-Related Retinitis Pigmentosa

March 11, 2026 • 2 mins

First-of-its-kind small molecule therapy targets protein misfolding at the root of RHO-adRP

Listen

Watch

Mark as Played

Opus Genetics Reports Promising Early Results from BEST1 Gene Therapy Trial

March 2, 2026 • 2 mins

First patient shows vision improvements with a good safety profile.

Listen

Watch

Mark as Played

Popular Podcasts

Stuff You Should Know

If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

Dateline NBC

Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

The Bobby Bones Show

Listen to 'The Bobby Bones Show' by downloading the daily full replay.

The Joe Rogan Experience

The official podcast of comedian Joe Rogan.

The Clay Travis and Buck Sexton Show

The Clay Travis and Buck Sexton Show. Clay Travis and Buck Sexton tackle the biggest stories in news, politics and current events with intelligence and humor. From the border crisis, to the madness of cancel culture and far-left missteps, Clay and Buck guide listeners through the latest headlines and hot topics with fun and entertaining conversations and opinions.

Advertise With Us

Foundation Fighting Blindness

Episodes

.css-14f5ked{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:2;overflow:hidden;}Nanoscope’s investigational RP treatment MOGENRY advances toward FDA approval

.css-r6mb8g{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:1;overflow:hidden;}Eye on the Cure Podcast | Episode 103: Kenyetta McCurdy-Byrd and Heather Edwards

First patient treated with potential retinitis pigmentosa treatment from Sumitomo Pharma America

Tarsus plans to purchase Alkeus, developer of emerging Stargardt treatment

PRIMA retinal implant restores sight in patients with geographic atrophy from AMD

FDA accepts new drug application, prioritizes review for potential Stargardt treatment

Eye on the Cure Podcast | Episode 102: What is Venture Philanthropy?

Sepul Bio completes clinical trial enrollment for its USH2A retinitis pigmentosa treatment

FDA approves Lumvoa, a new treatment for thyroid eye disease

Belite Bio submits new drug application to FDA for its Stargardt treatment

Eye on the Cure Podcast | Episode 101: Dr. Patrick Staropoli

Potential Oral Stargardt Treatment Advances to Phase 3 Clinical Trial

Foundation Fighting Blindness Celebrates Bennett, Maguire, and High's Breakthrough Prize for Revolutionary Gene Therapy

Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline

VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy

Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment

Octant Bio Begins Clinical Testing Oral Treatment for Rhodopsin-Related Retinitis Pigmentosa

Opus Genetics Reports Promising Early Results from BEST1 Gene Therapy Trial

Popular Podcasts

Nanoscope’s investigational RP treatment MOGENRY advances toward FDA approval

Eye on the Cure Podcast | Episode 103: Kenyetta McCurdy-Byrd and Heather Edwards